Amidization of doxorubicin alleviates doxorubicin-induced contractile dysfunction and reduced survival in murine cardiomyocytes

Toxicology Letters

Volumn 178, Issue 3, 2008, Pages 197-201

  Turdi, Subat ^a,b   Xu, Peisheng ^c   Li, Qun ^a   Shen, Youqing ^c   Kerram, Parhat ^b   Ren, Jun ^a  

^a UNIVERSITY OF WYOMING   (United States)

^b XINJIANG MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WYOMING   (United States)

Author keywords

Amidization; Cardiac myocytes; Doxorubicin; Relengthening; ROS; Shortening

Indexed keywords

AMIDE; AMINE; DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CARDIOTOXICITY; CELL SURVIVAL; CYTOTOXICITY; HEART MUSCLE CELL; MALE; MOUSE; MUSCLE CONTRACTION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL RATE;

AMIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FORMAZANS; MICE; MUSCLE CONTRACTION; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PHTHALIC ANHYDRIDES; REACTIVE OXYGEN SPECIES; TETRAZOLIUM SALTS;

MURINAE;

EID: 43049174730     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.03.010     Document Type: Article

References (26)

1. (2+)-ATPase gene transcription. Circ. Res. 86 (2000) 8-14
2. 2+-handling mechanisms in the sarcoplasmic reticulum in the rat. Can. J. Physiol Pharmacol. 78 (2000) 329-338
3. Dong F., Fang C.X., Yang X., Zhang X., Lopez F.L., and Ren J. Cardiac overexpression of catalase rescues cardiac contractile dysfunction induced by insulin resistance: Role of oxidative stress, protein carbonyl formation and insulin sensitivity. Diabetologia 49 (2006) 1421-1433
4. Gong Y., Duvvuri M., and Krise J.P. Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multidrug-resistant human leukemic cell line HL-60. J Biol. Chem. 278 (2003) 50234-50239
5. Jones S.M., Kirby M.S., Harding S.E., Vescova G., Wanless R.B., Dalla Libera L.D., and Poole-Wilson P.A. Adriamycin cardiomyopathy in the rabbit: alterations in contractile proteins and myocyte function. Cardiovasc. Res. 24 (1990) 834-842
6. Kalyanaraman B., Joseph J., Kalivendi S., Wang S., Konorev E., and Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol. Cell Biochem. 234-235 (2002) 119-124
7. Kluger R., Chin J., and Choy W.W. Carboxylic acid participation in amide hydrolysis. reactivity of intermediates in the internally catalyzed hydrolysis of N-substituted 2,3-dimethylmaleamic acids. J. Am. Chem. Soc. 101 (1979) 6976-6980
8. Lee Y., Fukushima S., Bae Y., Hiki S., Ishii T., and Kataoka K. A protein nanocarrier from charge-conversion polymer in response to endosomal pH. J. Am. Chem. Soc. 129 (2007) 5362-5363
9. Lown J.W., Chen H.H., Plambeck J.A., and Acton E.M. Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects. Biochem. Pharmacol. 31 (1982) 575-581
10. Minotti G., Cairo G., and Monti E. Role of iron in anthracycline cardiotoxicity: new tunes for an old song?. FASEB J. 13 (1999) 199-212
11. Mushlin P.S., and Olson R.D. Anthracycline cardiotoxicity: new insights. Ration. Drug Ther. 22 (1988) 1-9
12. Myers C.E., McGuire W.P., Liss R.H., Ifrim I., Grotzinger K., and Young R.C. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197 (1977) 165-167
13. Olson R.D., and Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4 (1990) 3076-3086
14. Pacher P., Beckman J.S., and Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87 (2007) 315-424
15. Pacher P., Liaudet L., Bai P., Mabley J.G., Kaminski P.M., Virag L., Deb A., Szabo E., Ungvari Z., Wolin M.S., Groves J.T., and Szabo C. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107 (2003) 896-904
16. Pacher P., Liaudet L., Bai P., Virag L., Mabley J.G., Hasko G., and Szabo C. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J. Pharmacol. Exp. Ther. 300 (2002) 862-867
17. Priebe W., Van N.T., Burke T.G., and Perez-Soler R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs 4 (1993) 37-48
18. Privratsky J.R., Wold L.E., Sowers J.R., Quinn M.T., and Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 42 (2003) 206-212
19. Rajagopalan S., Politi P.M., Sinha B.K., and Myers C.E. Adriamycin-induced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res. 48 (1988) 4766-4769
20. Shan Y.X., Liu T.J., Su H.F., Samsamshariat A., Mestril R., and Wang P.H. Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. J. Mol. Cell Cardiol. 35 (2003) 1135-1143
21. Taylor A.L., and Bulkley B.H. Acute adriamycin cardiotoxicity: morphologic alterations in isolated perfused rabbit heart. Lab Invest. 47 (1982) 459-464
22. Wang G.X., Wang Y.X., Zhou X.B., and Korth M. Effects of doxorubicinol on excitation--contraction coupling in guinea pig ventricular myocytes. Eur. J. Pharmacol. 423 (2001) 99-107
23. Wold L.E., Aberle N.S., and Ren J. Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism. Cancer Detect. Prev. 29 (2005) 294-299
24. Wold L.E., Relling D.P., Colligan P.B., Scott G.I., Hintz K.K., Ren B.H., Epstein P.N., and Ren J. Characterization of contractile function in diabetic hypertensive cardiomyopathy in adult rat ventricular myocytes. J. Mol. Cell Cardiol. 33 (2001) 1719-1726
25. Xu P., Van Kirk E.A., Zhan Y., Murdoch W.J., Radosz M., and Shen Y. Targeted charge-reversal nanoparticles for nuclear drug delivery. Angew. Chem. Int. Ed Engl. 46 (2007) 4999-5002
26. Ye G., Metreveli N.S., Ren J., and Epstein P.N. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 52 (2003) 777-783